What is the current Price Target for the Allogene Therapeutics, Inc. stock?

The average Allogene Therapeutics, Inc. target price is $8.20. This is 545.67% higher than the current stock price. The highest price target is 1,002.36%, the lowest is 136.22%. 10 Analysts have issued a price target Allogene Therapeutics, Inc. 2026 .

How high will the Allogene Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Allogene Therapeutics, Inc. stock will rise. The performance of stocks, including the Allogene Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Allogene Therapeutics, Inc. stock today?

The performance of Allogene Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Allogene Therapeutics, Inc. stock fall?

The decline in Allogene Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Allogene Therapeutics, Inc. Forecast, price target & analysts

$1.27

8.55% yesterday

Nasdaq, Jun 02, 10:05 pm CET

ISIN

US0197701065

Symbol

ALLO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Allogene Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Allogene Therapeutics, Inc. Classifications & Recommendation:

Buy

86%

Hold

14%

Allogene Therapeutics, Inc. Price Target

Target Price	$8.20
Price	$1.27
Potential	545.67% register free of charge
Number of Estimates	10

	10 Analysts have issued a price target Allogene Therapeutics, Inc. 2026 . The average Allogene Therapeutics, Inc. target price is $8.20. This is 545.67% register free of charge higher than the current stock price. The highest price target is $14.00 1,002.36% register free of charge , the lowest is $3.00 136.22% register free of charge .
	A rating was issued by 14 analysts: 12 Analysts recommend Allogene Therapeutics, Inc. to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Allogene Therapeutics, Inc. stock has an average upside potential 2026 of 545.67% register free of charge . Most analysts recommend the Allogene Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.32	-1.06
	36.84%	19.70%
P/E		negative
EV/Sales		negative

6 Analysts have issued a Allogene Therapeutics, Inc. forecast for earnings per share. The average Allogene Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.32	36.84%
2025	$-1.06 19.70% Unlock
2026	$-0.96 9.43% Unlock
2027	$-1.11 15.63% Unlock
2028	$-0.95 14.41% Unlock
2029	$-0.29 69.47% Unlock

Current	-1.09	36.34%
2025	-1.20 10.55% Unlock
2026	-1.33 10.83% Unlock
2027	-1.15 13.53% Unlock
2028	-1.33 15.65% Unlock
2029	-4.32 224.81% Unlock

Allogene Therapeutics, Inc....

Current Allogene Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Citigroup	Locked ➜ Locked	Locked	May 15 2025
Baird	Locked ➜ Locked	Locked	May 14 2025
Oppenheimer	Locked ➜ Locked	Locked	May 14 2025
Piper Sandler	Locked ➜ Locked	Locked	May 14 2025
RBC Capital	Locked ➜ Locked	Locked	May 14 2025
Truist Securities	Locked ➜ Locked	Locked	May 14 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 19 2025

Analyst Rating	Date
Locked Citigroup: Locked ➜ Locked	May 15 2025
Locked Baird: Locked ➜ Locked	May 14 2025
Locked Oppenheimer: Locked ➜ Locked	May 14 2025
Locked Piper Sandler: Locked ➜ Locked	May 14 2025
Locked RBC Capital: Locked ➜ Locked	May 14 2025
Locked Truist Securities: Locked ➜ Locked	May 14 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 19 2025

Discover more stocks with a high price target

NIO ADR 51.46%

Alibaba Group Holding Ltd 39.77%

TUI 37.83%

Novo Nordisk 36.18%

MongoDB 29.93%

Tencent Holdings Ltd. 28.03%

BYD 25.29%

NVIDIA 23.99%

BioNTech SE - ADR 20.70%

Pfizer 19.80%

Adidas 19.39%

Porsche 19.21%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now